NCT01642758View on ClinicalTrials.gov

Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

January 31, 2013

Conditions
Beta Thalassemia Intermedia
Interventions
DRUG

Sodium 2,2 dimethylbutyrate

Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks

Trial Locations (1)

Unknown

Chronic Care Center, Beirut

Sponsors
All Listed Sponsors
collaborator

HemaQuest Pharmaceuticals Inc.

INDUSTRY

lead

Boston University

OTHER